---
title: "RO: 6% CER sales growth and robust pipeline offset currency headwinds in H1 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293561825.md"
description: "Sales grew 6% at constant exchange rates in H1 2026, driven by strong demand for innovative medicines and diagnostics, while Swiss franc appreciation weighed on reported results. Regulatory momentum was strong with five US FDA Priority Reviews and several key product launches.Original document: Roche Holding Ltd [RO] Earnings Release — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-23T05:18:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293561825.md)
  - [en](https://longbridge.com/en/news/293561825.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293561825.md)
generator: "portal-rs"
---

# RO: 6% CER sales growth and robust pipeline offset currency headwinds in H1 2026

Sales grew 6% at constant exchange rates in H1 2026, driven by strong demand for innovative medicines and diagnostics, while Swiss franc appreciation weighed on reported results. Regulatory momentum was strong with five US FDA Priority Reviews and several key product launches.

Original document: Roche Holding Ltd \[RO\] Earnings Release — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Puzo Michael J Makes New $1.23 Million Investment in Roche Holding AG $RHHBY](https://longbridge.com/en/news/296476210.md)
- [Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings Narratives](https://longbridge.com/en/news/293799255.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**